Table 3.
Adjusted Analyses of Factors Associated with Mortality After Liver Transplantation for Hepatocellular Carcinoma.
| 30-day mortality |
90-day mortalityb |
|||
|---|---|---|---|---|
| N = 7171 |
N = 6988 |
|||
| Characteristic | OR (95% CI) | P-valuea | OR (95% CI) | P-valuea |
| Age at diagnosis (years) | — | — | 1.041 (1.012-1.072) | .006 |
| Race | — | — | — | — |
| White | — | — | 1.00 (Reference) | |
| African American | — | — | .874 (.442-1.728) | .699 |
| Asian/PI | — | — | .940 (.444-1.991) | .871 |
| Hispanic | — | — | .395 (.169-.922) | .027 |
| Other/unknown | — | — | 2.158 (1.032-4.516) | .041 |
| Miles to hospital | .999 (.997-1.000) | .066 | — | — |
| Insurance type | <.001 | <.001 | ||
| Private | 1.00 (Reference) | 1.00 (Reference) | ||
| Medicaid | 2.272 (1.440-3.585) | <.001 | 1.350 (.736-2.477) | .332 |
| Medicare | 1.834 (1.27-2.634) | .001 | .716 (.440-.168) | .181 |
| Not insured | 1.035 (.320-3.350) | .954 | 2.397 (1.060-5.420) | .036 |
| Other/unknown | 3.666 (1.754-7.664) | .001 | 4.367 (2.115-9.016) | <.001 |
| AJCC cancer stage | .005 | — | — | |
| Stage I | 1.00 (Reference) | — | — | |
| Stage II | .658 (.456-.950) | .025 | — | — |
| Stage III | 1.455 (.792-2.676) | .227 | — | — |
| Stage IV | 4.090 (1.173-14.265) | .027 | — | — |
| Unknown | 1.023 (.618-1.695) | .928 | — | — |
| Academic hospital (vs. Communityc) | 1.703 (.991-2.928) | .054 | .506 (.320-.801) | .004 |
| Care transitions | .669 (.454-.987) | .043 | — | — |
| Length of stay (days) | .879 (.847-.912) | <.001 | 1.029 (1.023-1.035) | <.001 |
| Readmission | .347 (.152-.791) | .012 | 1.627 (.987-2.682) | .057 |
Abbreviations: AJCC, American Joint Committee on Cancer, CI, confidence interval, HCC, hepatocellular carcinoma; OR, odds ratio.
a
P-values calculated using multivariable logistic regression.
b
Analysis includes patients who were alive for at least 30 days after surgery.
c
Includes comprehensive community cancer programs.